{
    "root": "744f7365-d1a1-41cc-a8bc-451b32b2600f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Gadavist",
    "value": "20250305",
    "ingredients": [
        {
            "name": "TROMETHAMINE",
            "code": "023C2WHX2V"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "GADOBUTROL",
            "code": "1BJ477IO2L"
        }
    ],
    "indications": "gadavist gadolinium-based contrast agent indicated magnetic resonance imaging ( mri ) : \u2022 detect visualize areas disrupted blood brain barrier ( bbb ) and/or abnormal vascularity central nervous system adult pediatric patients ( including term neonates ) ( 1.1 ) \u2022 assess presence extent malignant breast disease adult patients ( 1.2 ) \u2022 evaluate known suspected supra-aortic renal artery disease adult pediatric patients ( including term neonates ) ( 1.3 ) \u2022 assess myocardial perfusion ( stress , rest ) late gadolinium enhancement adult patients known suspected coronary artery disease ( cad ) ( 1.4 )",
    "contraindications": "\u2022 recommended dose adults pediatric patients ( including term neonates ) 0.1 ml/kg body weight ( 2.1 ) \u2022 administer intravenous bolus injection ( 2.2 ) \u2022 follow injection normal saline flush ( 2.2 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "gadavist contraindicated patients history severe hypersensitivity gadavist .",
    "indications_original": "Gadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging (MRI): \u2022 To detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates) ( 1.1 ) \u2022 To assess the presence and extent of malignant breast disease in adult patients ( 1.2 ) \u2022 To evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) ( 1.3 ) \u2022 To assess myocardial perfusion (stress, rest) and late gadolinium enhancement in adult patients with known or suspected coronary artery disease (CAD) ( 1.4 )",
    "contraindications_original": "\u2022 Recommended dose for adults and pediatric patients (including term neonates) is 0.1 mL/kg body weight ( 2.1 ) \u2022 Administer as an intravenous bolus injection ( 2.2 ) \u2022 Follow injection with a normal saline flush ( 2.2 )",
    "adverseReactions_original": "Gadavist is contraindicated in patients with history of severe hypersensitivity reactions to Gadavist."
}